Sugi Predict

Sugi Predict / Compounds / SCHEMBL561706

SCHEMBL561706

SCHEMBL561706

O=P(Cl)(Cl)Oc1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ HPGD P15428 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ LMNA P02545 4/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CYP2A6 P11509 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10015246 0.89 MEN1 (0.48) MEN1KMT2AHPGDSMN1; SMN2CYP2C19
SCHEMBL1913664 0.85 MEN1 (0.64) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL2065911 0.82 MEN1 (0.55) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL1059937 0.82 MEN1 (0.67) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL24082140 0.81 MEN1 (0.59) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL10622033 0.81 MEN1 (0.59) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL2065912 0.79 MEN1 (0.52) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL11507769 0.78 MEN1 (0.61) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL7028978 0.78 LMNA (0.44) MEN1KMT2ACA2CA9CA1
SCHEMBL1059938 0.78 MEN1 (0.61) MEN1KMT2AHPGDSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 652 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798607-B Preparation method and application of photo-curing resin 万华化学集团股份有限公司 2026-05-19 — — CN claimed
CN-119899354-A High-flame-retardance polyurethane heat-insulating material and preparation method thereof 绍兴市辰星聚氨酯有限公司 2025-04-29 — — CN claimed
CN-118459766-A Fluorosilicone oil containing phosphate and preparation method thereof 中国科学院上海有机化学研究所 2024-08-09 — — CN claimed
CN-116946990-A Wet phosphoric acid purifying process 宜都兴发化工有限公司 2023-10-27 — — CN claimed
CN-116902936-A Process for extracting impurities in wet phosphoric acid 宜都兴发化工有限公司 2023-10-20 — — CN claimed
CN-116835542-A Wet process phosphoric acid cation removing method 宜都兴发化工有限公司 2023-10-03 — — CN claimed
CN-116750735-A Wet phosphoric acid purification method 宜都兴发化工有限公司 2023-09-15 — — CN claimed
CN-114807328-A Method for marking and identifying single-base resolution DNA 浙江大学 2022-07-29 — — CN claimed
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 — — US claimed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 — — US claimed
EP-2265624-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED Centre National de la Recherche Scientifique (FR) 2010-12-29 — — EP claimed
WO-2009115694-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-09-24 — — WO claimed
US-20080038867-A1 METHOD FOR MANUFACTURING A THIN FILM TRANSISTOR ARRAY PANEL SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-02-14 — — US claimed
EP-0295262-B1 PHENOLIC RESIN-POLYISOCYANATE BINDER SYSTEMS CONTAINING AN ORGANOHALOPHOSPHATE AND USE THEREOF ASHLAND OIL INC (US) 1994-09-07 — — EP claimed
EP-0295262-A4 PHENOLIC RESIN-POLYISOCYANATE BINDER SYSTEMS CONTAINING AN ORGANOHALOPHOSPHATE AND USE THEREOF. ASHLAND OIL INC (US) 1989-02-23 — — EP claimed
EP-0295262-A1 PHENOLIC RESIN-POLYISOCYANATE BINDER SYSTEMS CONTAINING AN ORGANOHALOPHOSPHATE AND USE THEREOF. ASHLAND OIL INC (US) 1988-12-21 — — EP claimed
WO-1987005039-A1 PHENOLIC RESIN-POLYISOCYANATE BINDER SYSTEMS CONTAINING AN ORGANOHALOPHOSPHATE AND USE THEREOF ASHLAND OIL, INC. (US) 1987-08-27 — — WO claimed
US-4683252-A Phenolic resin-polyisocyanate binder systems containing an organohalophosphate and use thereof ASHLAND OIL, INC. (US) 1987-07-28 — — US claimed
US-3965220-A AMINE CATALYST MONSANTO COMPANY (US) 1976-06-22 — — US claimed
JP-6056876-A — — None — — JP disclosed
JP-58135896-A — — None — — JP disclosed
JP-7145058-A — — None — — JP disclosed
JP-9059292-A — — None — — JP disclosed
JP-59190997-A — — None — — JP disclosed
US-12637441-B2 Prodrugs of the tyrosine kinase inhibitor for treating cancer Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-05-26 — — US disclosed
EP-4744667-A2 EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF The Queen's University Of Belfast (GB) 2026-05-20 — — EP disclosed
CN-119798607-B Preparation method and application of photo-curing resin 万华化学集团股份有限公司 2026-05-19 — — CN disclosed
EP-4700125-A2 OLIGOMERIC NUCLEIC ACID, AND PREPARATION METHOD THEREFORE AND USE THEREOF Suzhou Siran Biotechnology Co., Ltd. (CN) 2026-02-25 — — EP disclosed
US-20250368598-A1 CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES BHATTACHARYA SHRABANTI (US) 2025-12-04 — — US disclosed
EP-4650446-A1 SIRNA FOR INHIBITING EXPRESSION OF PROGRAMMED CELL DEATH 1 LIGAND 1 GENE, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Suzhou Siran Biotechnology Co., Ltd. (CN) 2025-11-19 — — EP disclosed
EP-3833359-B1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF SKYLARK BIOSCIENCE LLC (US) 2025-07-23 — — EP disclosed
US-20250163093-A1 EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2025-05-22 — — US disclosed
CN-119998255-A Catalytic carboxycarbonylation of olefins to form anhydrides 北卡罗来纳大学教堂山分校 2025-05-13 — — CN disclosed
EP-4543841-A2 CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES The University of North Carolina at Chapel Hill (US) 2025-04-30 — — EP disclosed
CN-119899354-A High-flame-retardance polyurethane heat-insulating material and preparation method thereof 绍兴市辰星聚氨酯有限公司 2025-04-29 — — CN disclosed
CN-119798607-A Preparation method and application of photo-curing resin 万华化学集团股份有限公司 2025-04-11 — — CN disclosed
CN-110662542-B Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and efficient and scalable synthesis of novel crystalline forms thereof 英国贝尔法斯特女王大学 2025-04-08 — — CN disclosed
CN-119731322-A Oligonucleotide and preparation method and application thereof 苏州时安生物技术有限公司 2025-03-28 — — CN disclosed
CN-119320417-A Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs, adenosine dinucleotide conjugates, and efficient and scalable synthesis of novel crystalline forms 英国贝尔法斯特女王大学 2025-01-17 — — CN disclosed
US-12195494-B2 Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2025-01-14 — — US disclosed
US-12162001-B2 Magnetic-nanoparticle-supported catalyst and method of making KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-12-10 — — US disclosed
US-12157114-B2 Method for making Fe3O4 magnetic catalysts KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-12-03 — — US disclosed
US-12157113-B2 Sonication method for making magnetic supported catalysts KING FAHD UNIVERSITY OF PETOLEUM AND MINERALS (SA) 2024-12-03 — — US disclosed
CN-117881783-B SiRNA for inhibiting apoptosis-ligand 1 gene expression, conjugate, pharmaceutical composition and application thereof 苏州时安生物技术有限公司 2024-12-03 — — CN disclosed
WO-2024217152-A2 OLIGOMERIC NUCLEIC ACID, AND PREPARATION METHOD THEREFORE AND USE THEREOF 苏州时安生物技术有限公司 2024-10-24 — — WO disclosed
US-20240297343-A1 NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS SODIUM ION BATTERY, NONAQUEOUS POTASSIUM ION BATTERY, METHOD FOR PRODUCING NONAQUEOUS SODIUM ION BATTERY, AND METHOD FOR PRODUCING NONAQUEOUS POTASSIUM ION BATTERY CENTRAL GLASS CO., LTD. (JP) 2024-09-05 — — US disclosed
US-20240293807-A1 METHOD FOR MAKING Fe3O4 MAGNETIC CATALYSTS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-09-05 — — US disclosed
US-20240286120-A1 SONICATION METHOD FOR MAKING MAGNETIC SUPPORTED CATALYSTS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-08-29 — — US disclosed
US-20240286121-A1 MAGNETIC-NANOPARTICLE-SUPPORTED CATALYST AND METHOD OF MAKING KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-08-29 — — US disclosed
WO-2024169908-A1 SIRNA FOR REGULATING EXPRESSION OF COMPLEMENT C5, AND CONJUGATE, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 苏州时安生物技术有限公司 2024-08-22 — — WO disclosed
WO-2024169306-A1 SIRNA FOR INHIBITING EXPRESSION OF PROGRAMMED CELL DEATH 1 LIGAND 1 GENE, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 苏州时安生物技术有限公司 2024-08-22 — — WO disclosed
CN-118459766-A Fluorosilicone oil containing phosphate and preparation method thereof 中国科学院上海有机化学研究所 2024-08-09 — — CN disclosed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 — — US disclosed
EP-4387977-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2024-06-26 — — EP disclosed
CN-118202054-A SiRNA for regulating complement C5 expression, conjugate, pharmaceutical composition and application thereof 苏州时安生物技术有限公司 2024-06-14 — — CN disclosed
US-11980875-B2 Method for making magnetic nanoparticle supported catalysts KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-05-14 — — US disclosed
EP-4362158-A1 NON-AQUEOUS ELECTROLYTE SOLUTION, NON-AQUEOUS SODIUM-ION BATTERY, NON-AQUEOUS POTASSIUM-ION BATTERY, METHOD FOR MANUFACTURING NON-AQUEOUS SODIUM-ION BATTERY, AND METHOD FOR MANUFACTURING NON-AQUEOUS POTASSIUM-ION BATTERY Central Glass Co., Ltd. (JP) 2024-05-01 — — EP disclosed
CN-117881783-A siRNA for inhibiting apoptosis-ligand 1 gene expression, conjugate, pharmaceutical composition and application thereof 苏州时安生物技术有限公司 2024-04-12 — — CN disclosed
US-20240091753-A1 METHOD FOR MAKING MAGNETIC NANOPARTICLE SUPPORTED CATALYSTS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-03-21 — — US disclosed
CN-112739352-B Compounds that activate AMP-activated protein kinase and uses thereof 斯凯拉克生物科技有限责任公司 2024-01-23 — — CN disclosed
WO-2023250180-A2 CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-12-28 — — WO disclosed
US-20230391815-A1 EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2023-12-07 — — US disclosed
US-11834469-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-12-05 — — US disclosed
US-11834469-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-12-05 — — US disclosed
US-11834469-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-12-05 — — US disclosed
CN-112442011-B Prodrug compound and application thereof in treating cancers 润佳（苏州）医药科技有限公司 2023-11-14 — — CN disclosed
CN-116946990-A Wet phosphoric acid purifying process 宜都兴发化工有限公司 2023-10-27 — — CN disclosed
CN-219897131-U Wet phosphoric acid purifying system 宜都兴发化工有限公司 2023-10-27 — — CN disclosed
CN-116902936-A Process for extracting impurities in wet phosphoric acid 宜都兴发化工有限公司 2023-10-20 — — CN disclosed
US-11779590-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-10-10 — — US disclosed
US-11779590-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-10-10 — — US disclosed
US-11779590-B2 AMP-activated protein kinase activating compounds and uses thereof SKYLARK BIOSCIENCE LLC (US) 2023-10-10 — — US disclosed
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
CN-116835542-A Wet process phosphoric acid cation removing method 宜都兴发化工有限公司 2023-10-03 — — CN disclosed
CN-116750735-A Wet phosphoric acid purification method 宜都兴发化工有限公司 2023-09-15 — — CN disclosed
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases MSD INTERNATIONAL GMBH (CH) 2023-08-22 — — US disclosed
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases MSD INTERNATIONAL GMBH (CH) 2023-08-22 — — US disclosed
US-11712715-B2 Surface modification in the vapor phase Quantum-Si Incorporated (US) 2023-08-01 — — US disclosed
US-20230175030-A1 NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES Nuclera Nucleics Ltd. (GB) 2023-06-08 — — US disclosed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 — — EP disclosed
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-06-01 — — US disclosed
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-06-01 — — US disclosed
CN-111051325-B Spirothiocyclobutane nucleosides 詹森药业有限公司 2023-05-16 — — CN disclosed
US-20230086177-A1 PROCESS FOR PREPARING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2023-03-23 — — US disclosed
US-20230069332-A1 PROCESS FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2023-03-02 — — US disclosed
WO-2023023527-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2023-02-23 — — WO disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
US-20220411578-A1 PROCESS FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2022-12-29 — — US disclosed
WO-2022270561-A1 NON-AQUEOUS ELECTROLYTE SOLUTION, NON-AQUEOUS SODIUM-ION BATTERY, NON-AQUEOUS POTASSIUM-ION BATTERY, METHOD FOR MANUFACTURING NON-AQUEOUS SODIUM-ION BATTERY, AND METHOD FOR MANUFACTURING NON-AQUEOUS POTASSIUM-ION BATTERY セントラル硝子株式会社 2022-12-29 — — WO disclosed
CN-115210291-A Method for producing polyether carbonate polyols 科思创德国股份有限公司 2022-10-18 — — CN disclosed
CN-115190893-A Method for producing polyether carbonate polyols 科思创德国股份有限公司 2022-10-14 — — CN disclosed
EP-3904365-B1 CHEMICAL COMPOUNDS NuCana plc (GB) 2022-09-07 — — EP disclosed
CN-114807328-A Method for marking and identifying single-base resolution DNA 浙江大学 2022-07-29 — — CN disclosed
EP-3321275-B1 CRYSTALLINE FORM OF SOFOSBUVIR GILEAD SCIENCES INC (US) 2022-07-13 — — EP disclosed
EP-3321275-B1 CRYSTALLINE FORM OF SOFOSBUVIR GILEAD SCIENCES INC (US) 2022-07-13 — — EP disclosed
CN-114729115-A Method for producing polyether carbonate polyols 科思创知识产权两合公司 2022-07-08 — — CN disclosed
EP-4021912-A1 PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2022-07-06 — — EP disclosed
US-11345720-B2 Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2022-05-31 — — US disclosed
US-20220133765-A1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF SKYLARK BIOSCIENCE LLC (US) 2022-05-05 — — US disclosed
US-20220133765-A1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF SKYLARK BIOSCIENCE LLC (US) 2022-05-05 — — US disclosed
US-20220112172-A1 PROCESS FOR PRODUCING DIOL COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2022-04-14 — — US disclosed
US-20220106350-A1 EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2022-04-07 — — US disclosed
EP-3969586-A1 NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES Nuclera Nucleics Ltd (GB) 2022-03-23 — — EP disclosed
US-11267844-B2 Spirothietane nucleosides JANSSEN PHARMACEUTICA NV (BE) 2022-03-08 — — US disclosed
WO-2021262826-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2021-12-30 — — WO disclosed
EP-3676276-B1 SPIROTHIETANE NUCLEOSIDES JANSSEN PHARMACEUTICA NV (BE) 2021-12-08 — — EP disclosed
EP-3912984-A1 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV Janssen BioPharma, Inc. (US) 2021-11-24 — — EP disclosed
EP-3904365-A1 CHEMICAL COMPOUNDS NuCana plc (GB) 2021-11-03 — — EP disclosed
EP-3290428-B1 TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE GILEAD PHARMASSET LLC (US) 2021-10-13 — — EP disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 — — US disclosed
US-20210277181-A1 PROCESS FOR SEPARATING GASEOUS CONSTITUENTS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2021-09-09 — — US disclosed
CN-113316604-A Process for preparing diols 科思创知识产权两合公司 2021-08-27 — — CN disclosed
US-20210230209-A1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF SKYLARK BIOSCIENCE LLC (US) 2021-07-29 — — US disclosed
US-20210230209-A1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF SKYLARK BIOSCIENCE LLC (US) 2021-07-29 — — US disclosed
US-20210205339-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES MSD INTERNATIONAL GMBH (CH) 2021-07-08 — — US disclosed
US-20210205339-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES MSD INTERNATIONAL GMBH (CH) 2021-07-08 — — US disclosed
EP-3102215-B1 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION RIBOSCIENCE LLC (US) 2021-06-16 — — EP disclosed
EP-3833359-A2 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF Skylark Bioscience LLC (US) 2021-06-16 — — EP disclosed
US-20210171426-A1 PROCESS FOR PRODUCING POLYOL COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2021-06-10 — — US disclosed
US-20210139524-A1 SPIROTHIETANE NUCLEOSIDES JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 — — US disclosed
US-20210139523-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. (US) 2021-05-13 — — US disclosed
US-20210139524-A1 SPIROTHIETANE NUCLEOSIDES JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 — — US disclosed
US-20210129179-A1 SURFACE MODIFICATION IN THE VAPOR PHASE Quantum-Si Incorporated 2021-05-06 — — US disclosed
CN-112739352-A Compounds that activate AMP-activated protein kinase and uses thereof 斯凯拉克生物科技有限责任公司 2021-04-30 — — CN disclosed
CN-105085592-B N- [ (2' R) -2' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same 吉利德制药有限责任公司 2021-04-27 — — CN disclosed
US-20210106604-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2021-04-15 — — US disclosed
CN-112654660-A Method for separating out gas components 科思创知识产权两合公司 2021-04-13 — — CN disclosed
US-10968248-B2 Trinucleotide mRNA cap analogs Arcturus, Inc. (US) 2021-04-06 — — US disclosed
US-20210078970-A1 PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
CN-112513137-A Process for producing polyols 科思创知识产权两合公司 2021-03-16 — — CN disclosed
CN-112442011-A Prodrug compound and application thereof in treating cancer 润佳（苏州）医药科技有限公司 2021-03-05 — — CN disclosed
WO-2021035360-A1 PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-04 — — WO disclosed
US-20210054145-A1 PROCESS FOR PREPARING POLYETHER CARBONATE POLYOLS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2021-02-25 — — US disclosed
EP-2935303-B1 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV JANSSEN BIOPHARMA INC (US) 2021-02-17 — — EP disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 — — US disclosed
CN-105979951-B 4' -difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication 里博科学有限责任公司 2020-12-25 — — CN disclosed
WO-2020229831-A1 NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES NUCLERA NUCLEICS LTD (GB) 2020-11-19 — — WO disclosed
CN-111757902-A Method for producing polyether carbonate polyols 科思创知识产权两合公司 2020-10-09 — — CN disclosed
US-10793591-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-10-06 — — US disclosed
EP-3160476-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION JANSSEN BIOPHARMA INC (US) 2020-09-30 — — EP disclosed
US-10780105-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-09-22 — — US disclosed
EP-3676276-A1 SPIROTHIETANE NUCLEOSIDES Janssen Pharmaceutica NV (BE) 2020-07-08 — — EP disclosed
US-10683320-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-06-16 — — US disclosed
WO-2020114742-A1 SELF-ASSEMBLED MONOLAYER FOR ELECTRODE MODIFICATION AND DEVICE COMPRISING SUCH SELF-ASSEMBLED MONOLAYER MERCK PATENT GMBH (DE) 2020-06-11 — — WO disclosed
US-10662314-B2 Method for producing polyether carbonate polyols COVESTRO DEUTSCHLAND AG (DE) 2020-05-26 — — US disclosed
CN-111051325-A Spirothiacyclobutanenucleosides 詹森药业有限公司 2020-04-21 — — CN disclosed
US-20200040026-A1 TRINUCLEOTIDE MRNA CAP ANALOGS ARCTURUS THERAPEUTICS, INC. 2020-02-06 — — US disclosed
EP-3541825-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES Idenix Pharmaceuticals LLC. (US) 2019-09-25 — — EP disclosed
US-RE47589-E1 Phosphoramidate compounds and methods of use NuCana plc (GB) 2019-09-03 — — US disclosed
US-RE47589-E1 Phosphoramidate compounds and methods of use NuCana plc (GB) 2019-09-03 — — US disclosed
EP-3529255-A1 TRINUCLEOTIDE MRNA CAP ANALOGS Arcturus Therapeutics, Inc. (US) 2019-08-28 — — EP disclosed
US-10307439-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2019-06-04 — — US disclosed
EP-3486251-A1 CHEMICAL COMPOUNDS NuCana plc (GB) 2019-05-22 — — EP disclosed
US-20190085011-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2019-03-21 — — US disclosed
WO-2019043177-A1 SPIROTHIETANE NUCLEOSIDES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — WO disclosed
WO-2019043177-A1 SPIROTHIETANE NUCLEOSIDES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — WO disclosed
US-20190054108-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2019-02-21 — — US disclosed
US-20190031703-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2019-01-31 — — US disclosed
EP-3421482-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Alios Biopharma, Inc. (US) 2019-01-02 — — EP disclosed
EP-3040340-B1 CHEMICAL COMPOUNDS NuCana plc (GB) 2018-11-14 — — EP disclosed
US-10125217-B2 Method for producing polyether carbonate polyols COVESTRO DEUTSCHLAND AG (DE) 2018-11-13 — — US disclosed
EP-3172216-B1 2,3'-ANHYDRO-2'-DÉOXY-5-FLUOROURIDINE DERIVATIVES WITH CYTOTOXIC ACTIVITY, A MANUFACTURING PROCESS AND USE THEREOF ADAM MICKIEWICZ UNIV (PL) 2018-10-10 — — EP disclosed
US-10092649-B2 4′-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication RIBOSCIENCE LLC (US) 2018-10-09 — — US disclosed
US-10040901-B2 Method for producing polyether carbonate polyols COVESTRO DEUTSCHLAND AG (DE) 2018-08-07 — — US disclosed
WO-2018134399-A1 NOVEL PRODRUGS OF MIZORIBINE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2018-07-26 — — WO disclosed
WO-2018091542-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES IDENIX PHARMACEUTICALS LLC (US) 2018-05-24 — — WO disclosed
EP-1928475-B1 ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES RIBOSCIENCE LLC (US) 2018-05-23 — — EP disclosed
EP-3321275-A1 CRYSTALLINE FORM OF SOFOSBUVIR Gilead Pharmasset LLC (US) 2018-05-16 — — EP disclosed
WO-2018075827-A1 TRINUCLEOTIDE MRNA CAP ANALOGS ARCTURUS THERAPEUTICS, INC. (US) 2018-04-26 — — WO disclosed
US-20180105551-A1 TRINUCLEOTIDE MRNA CAP ANALOGS ARCTURUS THERAPEUTICS, INC. 2018-04-19 — — US disclosed
EP-2955190-B1 Chemical compounds NuCana plc (GB) 2018-03-28 — — EP disclosed
CN-107846883-A The solvent-free phosphorylation of selectivity 可劳迈戴斯有限公司 2018-03-27 — — CN disclosed
US-20180079774-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2018-03-22 — — US disclosed
US-20180079774-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2018-03-22 — — US disclosed
US-20180079890-A1 METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG 2018-03-22 — — US disclosed
EP-3290428-A1 TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE Gilead Pharmasset LLC (US) 2018-03-07 — — EP disclosed
EP-2691409-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2018-02-21 — — EP disclosed
US-20180044369-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2018-02-15 — — US disclosed
US-20180044367-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. 2018-02-15 — — US disclosed
US-20180044367-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. 2018-02-15 — — US disclosed
EP-2923734-B1 PURINE ANALOGUES AND THEIR USE AS IMMUNOSUPPRESSIVE AGENTS UNIV LEUVEN KATH (BE) 2018-01-10 — — EP disclosed
US-9862743-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2018-01-09 — — US disclosed
US-9815965-B2 Method for producing polyether carbonate polyols COVESTRO DEUTSCHLAND AG (DE) 2017-11-14 — — US disclosed
US-9815864-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-11-14 — — US disclosed
US-9815864-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-11-14 — — US disclosed
US-20170296664-A1 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication RIBOSCIENCE LLC 2017-10-19 — — US disclosed
EP-2913337-B1 PROCESS FOR THE PRODUCTION OF SOFOSBUVIR GILEAD PHARMASSET LLC (US) 2017-09-06 — — EP disclosed
US-9708357-B2 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication Riboscience, LLC (US) 2017-07-18 — — US disclosed
EP-3172216-A1 2,3'-Anhydro-2'-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application Adam Mickiewicz University (PL) 2017-05-31 — — EP disclosed
US-20170143749-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-05-25 — — US disclosed
US-20170143749-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-05-25 — — US disclosed
US-20170143751-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2017-05-25 — — US disclosed
US-20170143751-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2017-05-25 — — US disclosed
EP-2609923-B1 PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE GILEAD PHARMASSET LLC (US) 2017-05-24 — — EP disclosed
US-20170137569-A1 Method for Producing Polyether Carbonate Polyols COVESTRO DEUTSCHLAND AG (DE) 2017-05-18 — — US disclosed
US-9637512-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2017-05-02 — — US disclosed
US-9637512-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2017-05-02 — — US disclosed
US-9637512-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2017-05-02 — — US disclosed
EP-2852604-B1 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC (US) 2017-04-12 — — EP disclosed
EP-2794628-B1 4'-AZIDO-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC (US) 2017-03-29 — — EP disclosed
US-9603863-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-03-28 — — US disclosed
US-9603863-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-03-28 — — US disclosed
US-20170037077-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-02-09 — — US disclosed
US-20170037077-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-02-09 — — US disclosed
US-20170037075-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-02-09 — — US disclosed
US-20170037075-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-02-09 — — US disclosed
EP-3102215-A2 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION Riboscience LLC (US) 2016-12-14 — — EP disclosed
US-20160264727-A1 METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2016-09-15 — — US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 — — US disclosed
EP-1646639-B1 NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS NUCANA BIOMED LTD (GB) 2016-08-17 — — EP disclosed
US-20160208080-A1 METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2016-07-21 — — US disclosed
EP-2432792-B1 AND PROCESS FOR THE PREPARATION OF N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER GILEAD PHARMASSET LLC (US) 2016-07-06 — — EP disclosed
EP-3040340-A1 CHEMICAL COMPOUNDS NuCana BioMed Limited (GB) 2016-07-06 — — EP disclosed
US-9370569-B2 4′-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication RIBOSCIENCE LLC (US) 2016-06-21 — — US disclosed
US-9284342-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2016-03-15 — — US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 — — US disclosed
US-9260468-B1 2,3′-anhydro-2′-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application ADAM MICKIEWICZ UNIVERSITY (PL) 2016-02-16 — — US disclosed
US-20160039858-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-02-11 — — US disclosed
US-20160039858-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-02-11 — — US disclosed
US-9249174-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2016-02-02 — — US disclosed
US-9249174-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2016-02-02 — — US disclosed
US-20160024136-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-01-28 — — US disclosed
US-20160024133-A1 2,3'-ANHYDRO-2'-DEOXY-5-FLUOROURIDINE DERIVATIVES WITH CYTOTOXIC ACTIVITY, A MANUFACTURING PROCESS AND APPLICATION ADAM MICKIEWICZ UNIVERSITY (PL) 2016-01-28 — — US disclosed
US-20160024136-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-01-28 — — US disclosed
US-9243022-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2016-01-26 — — US disclosed
US-9243022-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2016-01-26 — — US disclosed
US-9243025-B2 Compounds and pharmaceutical compositions for the treatment of viral infections IDENIX PHARMACEUTICALS, LLC (US) 2016-01-26 — — US disclosed
US-20160016987-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-01-21 — — US disclosed
US-20160016987-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. 2016-01-21 — — US disclosed
US-9221822-B2 Thiazolopyrimidine modulators as immunosuppressive agents KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) 2015-12-29 — — US disclosed
US-20150366888-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
US-20150366888-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
US-20150366887-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
US-20150366887-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-12-24 — — US disclosed
EP-2955190-A2 Chemical compounds NuCana BioMed Limited (GB) 2015-12-16 — — EP disclosed
US-9206217-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2015-12-08 — — US disclosed
US-9206217-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2015-12-08 — — US disclosed
US-9169256-B2 Artificial nucleic acids ELITECHGROUP B.V. (NL) 2015-10-27 — — US disclosed
EP-2923734-A1 Purine analogues and their use as immunosuppressive agents Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2015-09-30 — — EP disclosed
EP-2913337-A1 N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION Gilead Pharmasset LLC (US) 2015-09-02 — — EP disclosed
EP-2552930-B1 CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE GILEAD PHARMASSET LLC (US) 2015-08-26 — — EP disclosed
EP-2910562-A1 N-[(2'r)-2'-deoxy-2 '-fluoro-2'-methyl-p-phenyl-5 '-uridylyl]-l-alanine 1-methylethyl ester in crystalline form Gilead Pharmasset LLC (US) 2015-08-26 — — EP disclosed
US-9109001-B2 3′,5′-cyclic phosphoramidate prodrugs for HCV infection IDENIX PHARMACEUTICALS, INC. (US) 2015-08-18 — — US disclosed
WO-2015120237-A2 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION RIBOSCIENCE LLC (US) 2015-08-13 — — WO disclosed
US-20150225441-A1 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication RIBOSCIENCE LLC 2015-08-13 — — US disclosed
WO-2015054465-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2015-04-16 — — WO disclosed
US-20150105341-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-04-16 — — US disclosed
US-20150105341-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-04-16 — — US disclosed
WO-2015050468-A1 2,3'-Anhydro-2'-deoxy-5-fluorouridine derivatives with cytotoxic activity, a manufacturing process and application ADAM MICKIEWICZ UNIVERSITY (PL) 2015-04-09 — — WO disclosed
EP-2852604-A1 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION IDENIX Pharmaceuticals, Inc. (US) 2015-04-01 — — EP disclosed
US-20150038494-A1 Thiazolopyrimidine Modulators as Immunosuppressive Agents KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2015-02-05 — — US disclosed
US-20150011497-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-01-08 — — US disclosed
US-20150011497-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Pharmaceuticals, Inc. 2015-01-08 — — US disclosed
WO-2014209979-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-12-31 — — WO disclosed
US-20140369959-A1 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC 2014-12-18 — — US disclosed
US-8901132-B2 Thiazolopyrimidine modulators as immunosuppressive agents KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-12-02 — — US disclosed
WO-2014175974-A2 ARTIFICIAL NUCLEIC ACIDS ELITECH HOLDING B.V. (NL) 2014-10-30 — — WO disclosed
EP-2794628-A1 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION F.HOFFMANN-LA ROCHE AG (CH) 2014-10-29 — — EP disclosed
US-20140275508-A1 ARTIFICIAL NUCLEIC ACIDS ELITECH HOLDING B.V. (NL) 2014-09-18 — — US disclosed
US-20140205566-A1 CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-07-24 — — US disclosed
US-20140205566-A1 CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-07-24 — — US disclosed
US-20140205566-A1 CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-07-24 — — US disclosed
US-20140179627-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — US disclosed
US-20140179627-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — US disclosed
US-20140179910-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — US disclosed
WO-2014100505-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — WO disclosed
US-20140179910-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — US disclosed
WO-2014082935-A1 CYCLIC NUCLEOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-06-05 — — WO disclosed
US-8735569-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-05-27 — — US disclosed
US-8735569-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-05-27 — — US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 — — US disclosed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 — — US disclosed
US-8648054-B2 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication ROCHE PALO ALTO LLC (US) 2014-02-11 — — US disclosed
EP-2691409-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX Pharmaceuticals, Inc. (US) 2014-02-05 — — EP disclosed
US-8642756-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-02-04 — — US disclosed
US-8642756-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-02-04 — — US disclosed
US-8637531-B2 Pyrido(3,2-d)pyridmidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-01-28 — — US disclosed
US-8633309-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-01-21 — — US disclosed
US-8633309-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-01-21 — — US disclosed
US-8629263-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-01-14 — — US disclosed
US-8629263-B2 Nucleoside phosphoramidates GILEAD PHARMASSET LLC (US) 2014-01-14 — — US disclosed
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 — — US disclosed
US-20130315866-A1 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC 2013-11-28 — — US disclosed
WO-2013177188-A1 3',5'-CYCLIC PHOSPHORAMIDATE PRODRUGS FOR HCV INFECTION IDENIX PHARMACEUTICALS, INC. (US) 2013-11-28 — — WO disclosed
US-20130310551-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD SCIENCES, INC. 2013-11-21 — — US disclosed
US-20130288997-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD SCIENCES, INC. 2013-10-31 — — US disclosed
US-20130288997-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD SCIENCES, INC. 2013-10-31 — — US disclosed
US-8563968-B2 Electroluminescent device DAI NIPPON PRINTING CO., LTD. (JP) 2013-10-22 — — US disclosed
US-20130237491-A1 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION ROCHE PALO ALTO LLC (US) 2013-09-12 — — US disclosed
EP-2609923-A2 Nucleoside Phosphoramidates Gilead Pharmasset LLC (US) 2013-07-03 — — EP disclosed
WO-2013092447-A1 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 — — WO disclosed
US-20130165401-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-06-27 — — US disclosed
US-20130165644-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-06-27 — — US disclosed
US-20130165644-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-06-27 — — US disclosed
US-20130165401-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-06-27 — — US disclosed
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-05-30 — — US disclosed
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES GILEAD PHARMASSET LLC (US) 2013-05-30 — — US disclosed
US-8431588-B2 Cyclopropyl polymerase inhibitors JANSSEN PRODUCTS, LP (US) 2013-04-30 — — US disclosed
US-8431588-B2 Cyclopropyl polymerase inhibitors JANSSEN PRODUCTS, LP (US) 2013-04-30 — — US disclosed
EP-1501929-B1 CGRP BINDING NUCLEIC ACIDS NOXXON PHARMA AG (DE) 2013-03-27 — — EP disclosed
US-8384064-B2 Electroluminescent device DAI NIPPON PRINTING CO., LTD. (JP) 2013-02-26 — — US disclosed
US-8338435-B2 Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections GILEAD SCIENCES, INC. (US) 2012-12-25 — — US disclosed
US-20120309705-A1 NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES NOVADEX PHARMACEUTICALS AB (SE) 2012-12-06 — — US disclosed
US-8325509-B2 Memory device SONY CORPORATION (JP) 2012-12-04 — — US disclosed
EP-2120565-B1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK SHARP & DOHME (US) 2012-11-28 — — EP disclosed
WO-2012154321-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS, INC. (US) 2012-11-15 — — WO disclosed
EP-2513131-A1 NOVEL 3´-DEOXY-3´-METHYLIDENE- -L-NUCLEOSIDES Novadex Pharmaceuticals AB (SE) 2012-10-24 — — EP disclosed
EP-2141172-B1 Cyclopropyl polymerase inhibitors JANSSEN PRODUCTS LP (US) 2012-10-24 — — EP disclosed
US-20120251487-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC 2012-10-04 — — US disclosed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 — — US disclosed
CN-101779306-B Memory device SONY CORP 2012-06-20 — — CN disclosed
US-8148349-B2 Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-04-03 — — US disclosed
US-8148349-B2 Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-04-03 — — US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 — — US disclosed
US-20120046278-A1 THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-02-23 — — US disclosed
US-8114994-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2012-02-14 — — US disclosed
US-20120034184-A1 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION DEVOS RENE ROBERT (GB) 2012-02-09 — — US disclosed
EP-2405973-A2 THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-01-18 — — EP disclosed
US-8071567-B2 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication ROCHE PALO ALTO LLC (US) 2011-12-06 — — US disclosed
US-20110286263-A1 MEMORY DEVICE SONY CORPORATION (JP) 2011-11-24 — — US disclosed
US-20110251152-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-13 — — US disclosed
US-20110251152-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-13 — — US disclosed
WO-2011123645-A2 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2011-10-06 — — WO disclosed
WO-2011075052-A1 NOVEL 3´-DEOXY-3´-METHYLIDENE- -L-NUCLEOSIDES NOVADEX PHARMACEUTICALS AB (SE) 2011-06-23 — — WO disclosed
US-7951787-B2 Phosphoramidate compounds and methods of use CARDIFF PROTIDES LIMITED (GB) 2011-05-31 — — US disclosed
US-7951787-B2 Phosphoramidate compounds and methods of use CARDIFF PROTIDES LIMITED (GB) 2011-05-31 — — US disclosed
US-7951787-B2 Phosphoramidate compounds and methods of use CARDIFF PROTIDES LIMITED (GB) 2011-05-31 — — US disclosed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 — — US disclosed
US-20110092460-A1 CYCLOPROPYL POLYMERASE INHIBITORS CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) 2011-04-21 — — US disclosed
US-20110092460-A1 CYCLOPROPYL POLYMERASE INHIBITORS CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) 2011-04-21 — — US disclosed
US-7915232-B2 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication ROCHE PALO ALTO LLC (US) 2011-03-29 — — US disclosed
US-7879991-B2 CGRP binding nucleic acids NOXXON PHARMA AG (DE) 2011-02-01 — — US disclosed
US-7879815-B2 inhibitors of viral polymerases such as 5'-O-[[4-chloro-5-methyl-2-(1-methylethyl)phenoxy][[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phosphinyl]-2'-C-methylcytidine, used for the treatment of hepatitis C virus infection in mammals MERCK SHARP & DOHME CORP. (US) 2011-02-01 — — US disclosed
EP-2265624-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED Centre National de la Recherche Scientifique (FR) 2010-12-29 — — EP disclosed
WO-2010135569-A1 N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION PHARMASSET, INC. (US) 2010-11-25 — — WO disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed
US-20100298257-A1 NUCLEOSIDE PHOSPHORAMIDATES PHARMASSET, INC. (US) 2010-11-25 — — US disclosed
US-20100258789-A1 ELECTROLUMINESCENT DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2010-10-14 — — US disclosed
US-20100237323-A1 ELECTROLUMINESCENT DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2010-09-23 — — US disclosed
US-20100234316-A1 Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection MSD ITALIA S.R.L. (IT) 2010-09-16 — — US disclosed
WO-2010103130-A2 NOVEL BICYCLIC HETEROCYCLES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-09-16 — — WO disclosed
CN-101779306-A Memory device SONY CORP 2010-07-14 — — CN disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 — — US disclosed
EP-1439177-B1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane UNIV EMORY (US) 2010-05-26 — — EP disclosed
US-20100048559-A1 PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS Gilead Science, Inc (US) 2010-02-25 — — US disclosed
EP-2157095-A2 Synthesis of beta-L-2-Deoxy nucleosides Novartis Ag (CH) 2010-02-24 — — EP disclosed
US-20100022468-A1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK SHARP & DOHME LLC 2010-01-28 — — US disclosed
US-20100022468-A1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK SHARP & DOHME LLC 2010-01-28 — — US disclosed
US-20100003213-A1 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION DEVOS RENE ROBERT 2010-01-07 — — US disclosed
US-20100004192-A1 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication MARTIN JOSEPH ARMSTRONG 2010-01-07 — — US disclosed
WO-2010000459-A1 CYCLOPROPYL POLYMERASE INHIBITORS CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) 2010-01-07 — — WO disclosed
WO-2010000459-A1 CYCLOPROPYL POLYMERASE INHIBITORS CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) 2010-01-07 — — WO disclosed
EP-2141172-A1 Cyclopropyl polymerase inhibitors Ortho Biotech Products L.P. (US) 2010-01-06 — — EP disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 — — US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 — — US disclosed
US-7608601-B2 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication ROCHE PALO ALTO LLC (US) 2009-10-27 — — US disclosed
US-7608599-B2 Antiviral phosphoramidates ROCHE PALO ALTO LLC (US) 2009-10-27 — — US disclosed
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-10-22 — — US disclosed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 — — US disclosed
US-7595390-B2 Industrially scalable nucleoside synthesis NOVARTIS AG (CH) 2009-09-29 — — US disclosed
WO-2009115694-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-09-24 — — WO disclosed
EP-1828145-A4 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION UNIV EMORY (US) 2009-08-19 — — EP disclosed
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-06-11 — — US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 — — US disclosed
US-7501513-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2009-03-10 — — US disclosed
US-7495006-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2009-02-24 — — US disclosed
US-20090048190-A1 Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane LIOTTA DENNIS C 2009-02-19 — — US disclosed
EP-1620451-A4 INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS NOVARTIS AG (CH) 2009-02-18 — — EP disclosed
EP-1664052-B1 FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) ASTRAZENECA AB (SE) 2009-02-18 — — EP disclosed
WO-2009019000-A1 MEMORY DEVICE SONY CORPORATION (JP) 2009-02-12 — — WO disclosed
EP-1851217-B1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS 4 AZA IP NV (BE) 2009-02-11 — — EP disclosed
CN-101365699-A Pyrido (3, 2-D) pyrimidines and pharmaceutical compositions useful in medicine 4 AZA IP NV (BE) 2009-02-11 — — CN disclosed
EP-2023418-A1 Memory device Sony Corporation (JP) 2009-02-11 — — EP disclosed
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-02-05 — — US disclosed
WO-2009003669-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-01-08 — — WO disclosed
US-20080312227-A1 Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders 4 AZA BIOSCIENCE NV (BE) 2008-12-18 — — US disclosed
EP-1987050-A2 NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION Merck & Co., Inc. (US) 2008-11-05 — — EP disclosed
US-20080187580-A1 Therapeutic nucleosides EMORY UNIVERSITY, INC. 2008-08-07 — — US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 — — US disclosed
US-7402588-B2 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane EMORY UNIVERSITY (US) 2008-07-22 — — US disclosed
WO-2008077649-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS GILEAD SCIENCES, INC. (US) 2008-07-03 — — WO disclosed
WO-2008079206-A1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK & CO., INC. (US) 2008-07-03 — — WO disclosed
WO-2008077650-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-03 — — WO disclosed
WO-2008077651-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-03 — — WO disclosed
US-7390890-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2008-06-24 — — US disclosed
US-7371757-B2 Fused heterocycles as inhibitors of glutamate racemase(MURI) ASTRAZENECA AB (SE) 2008-05-13 — — US disclosed
EP-1639121-A4 SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES IDENIX CAYMAN LTD (KY) 2008-04-16 — — EP disclosed
US-20080083921-A1 SEMICONDUCTOR MEMORY DEVICE AND METHOD OF FORMING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-04-10 — — US disclosed
EP-1899332-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2008-03-19 — — EP disclosed
US-20080038867-A1 METHOD FOR MANUFACTURING A THIN FILM TRANSISTOR ARRAY PANEL SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-02-14 — — US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 — — WO disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 — — WO disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 — — WO disclosed
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2008-01-03 — — US disclosed
EP-1851217-A1 SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS 4 AZA IP NV (BE) 2007-11-07 — — EP disclosed
US-20070254312-A1 Protein Kinase Inhibitors and Methods for Identiying Same NATIONAL INSTITUTES OF HEALTH 2007-11-01 — — US disclosed
EP-1658081-B1 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA IP NV (BE) 2007-10-24 — — EP disclosed
US-7276506-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-10-02 — — US disclosed
EP-1831217-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2007-09-12 — — EP disclosed
EP-1828145-A2 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION EMORY UNIVERSITY (US) 2007-09-05 — — EP disclosed
WO-2007095269-A2 NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK & CO., INC. (US) 2007-08-23 — — WO disclosed
US-20070197561-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2007-08-23 — — US disclosed
EP-1673092-B1 HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY 4 AZA IP NV (BE) 2007-08-15 — — EP disclosed
EP-1663244-B1 PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. 4 AZA IP NV (BE) 2007-08-15 — — EP disclosed
US-7256064-B2 Organic semiconductor device DAI NIPPON PRINTING CO. LTD. (JP) 2007-08-14 — — US disclosed
EP-1808434-A2 Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B EMORY UNIVERSITY (US) 2007-07-18 — — EP disclosed
EP-1142891-B1 Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B UNIV EMORY (US) 2007-05-02 — — EP disclosed
US-7211653-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2007-05-01 — — US disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 — — US disclosed
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions 4 AZA BIOSCIENCE NV (BE) 2007-02-08 — — US disclosed
US-20070004721-A1 Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases 4 AZA BIOSCIENCE NV (BE) 2007-01-04 — — US disclosed
US-20070004761-A1 Pyrazolo [3,4-d] pyrimidine derivatives and their use in the treatment of h.pylori infection HETERO DRUGS LIMITED (IN) 2007-01-04 — — US disclosed
WO-2006135993-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2006-12-28 — — WO disclosed
EP-1585748-B1 PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION ASTRAZENECA AB (SE) 2006-12-27 — — EP disclosed
US-20060287314-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2006-12-21 — — US disclosed
US-20060276492-A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane LIOTTA DENNIS C 2006-12-07 — — US disclosed
EP-1186612-B1 PROCESS FOR THE PREPARATION OF CYTIDINE DERIVATIVES MITSUI CHEMICALS INC (JP) 2006-11-29 — — EP disclosed
EP-1644395-B1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-11-22 — — EP disclosed
WO-2006121820-A1 PHOSPHORAMIDATE PRODRUGS FOR TREATMENT OF VIRAL INFECTION VALEANT RESEARCH & DEVELOPMENT (US) 2006-11-16 — — WO disclosed
US-20060252781-A1 Fused heterocycles as inhibitors of glutamate racemase(muri) ASTRAZENECA AB (SE) 2006-11-09 — — US disclosed
US-20060229327-A1 Therapeutic nucleosides EMORY UNIVERSITY, INC. 2006-10-12 — — US disclosed
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY 2006-10-05 — — US disclosed
CN-1827108-A Use of cytosine derivative for preparing drug for treating cancer UNIV GEORGIA (US) 2006-09-06 — — CN disclosed
WO-2006087229-A1 SUBSTITUTED PYRIDO (2 , 3-D) PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS 4 AZA IP NV (BE) 2006-08-24 — — WO disclosed
US-20060189620-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2006-08-24 — — US disclosed
US-20060183700-A1 Cgrp binding nucleic acids NOXXON PHARMA AG (DE) 2006-08-17 — — US disclosed
WO-2006069805-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2006-07-06 — — WO disclosed
US-20060142238-A1 Chemical compounds NuCana plc (GB) 2006-06-29 — — US disclosed
WO-2006063281-A2 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION EMORY UNIVERSITY (US) 2006-06-15 — — WO disclosed
EP-1664052-A1 FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) AstraZeneca AB (SE) 2006-06-07 — — EP disclosed
EP-1663244-A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. 4 AZA Bioscience nv (BE) 2006-06-07 — — EP disclosed
US-7053100-B2 A cis isomer of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine has potent activity against hepatitis B virus infection; administration by rectal, nasal, topical, transdermal, vaginal, parenteral, intravenous injection EMORY UNIVERSITY, INC. (US) 2006-05-30 — — US disclosed
EP-1658081-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-05-24 — — EP disclosed
EP-1646639-A2 NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS University College Cardiff Consultants, Ltd. (GB) 2006-04-19 — — EP disclosed
CN-1251680-C Application of cytosine derivative in preparing medicine for treating tumor UNIV GEORGIA RES FOUND (US) 2006-04-19 — — CN disclosed
EP-1644395-A1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-04-12 — — EP disclosed
EP-1639121-A2 SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES Idenix (Cayman) Limited (KY) 2006-03-29 — — EP disclosed
US-20060054883-A1 Organic semiconductor device DAI NIPPON PRINTING CO., LTD. (JP) 2006-03-16 — — US disclosed
EP-1620451-A2 INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS Idenix (Cayman) Limited (KY) 2006-02-01 — — EP disclosed
EP-1404347-B1 4'-SUBSTITUDED NUCLEOSIDES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS HOFFMANN LA ROCHE (CH) 2006-01-18 — — EP disclosed
EP-1585748-A1 PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION AstraZeneca AB (SE) 2005-10-19 — — EP disclosed
US-20050215527-A1 Antiviral activity and resolution of 2-hydroxymethyl-5- (5-fluorocytosin-1-yl)-1, 3-oxathiolane EMORY UNIVERSITY 2005-09-29 — — US disclosed
EP-1023308-B1 INHIBITORS OF NUCLEOSIDE METABOLISM EINSTEIN COLL MED (US) 2005-09-07 — — EP disclosed
WO-2005025574-A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. 4 AZA BIOSCIENCE NV (BE) 2005-03-24 — — WO disclosed
US-20050059632-A1 Synthesis of beta-L-2'-deoxy nucleosides NOVARTIS AG (CH) 2005-03-17 — — US disclosed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 — — WO disclosed
WO-2005016929-A1 FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) ASTRAZENECA AB (SE) 2005-02-24 — — WO disclosed
US-20050038240-A1 Processes for preparing 4'-azido-nucleoside derivatives ROCHE PALO ALTO LLC 2005-02-17 — — US disclosed
WO-2005012327-A2 NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2005-02-10 — — WO disclosed
US-20050025994-A1 Organic electroluminescent element and method for producing the same DAI NIPPON PRINTING CO., LTD. (JP) 2005-02-03 — — US disclosed
US-20050026936-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2005-02-03 — — US disclosed
EP-1501929-A2 CGRP BINDING NUCLEIC ACIDS Grünenthal GmbH (DE) 2005-02-02 — — EP disclosed
WO-2005003374-A2 SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2005-01-13 — — WO disclosed
WO-2005000864-A1 PROCESSES FOR PREPARING 4’AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 — — WO disclosed
US-20050004148-A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane EMORY UNIVERSITY 2005-01-06 — — US disclosed
US-20050004357-A1 Industrially scalable nucleoside synthesis NOVARTIS AG (CH) 2005-01-06 — — US disclosed
US-20040266722-A1 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC 2004-12-30 — — US disclosed
US-6833361-B2 Compound for use in the treatment of viral diseases RIBAPHARM, INC. 2004-12-21 — — US disclosed
US-20040242610-A1 Therapeutic nucleosides EMORY UNIVERSITY, INC. 2004-12-02 — — US disclosed
US-6822090-B2 GENERATION OF PREFERENTIAL URIDINE DERIVATIVE; OBTAIN REACTION MIXTURE, EXPOSE TO TERTIARY AMINE, DEHYDRATING REACTANT AND AMMONIA, RECOVER CYTIDINE DERIVATIVE MITSUI CHEMICALS, INC. (JP) 2004-11-23 — — US disclosed
WO-2004096149-A2 INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS IDENIX (CAYMAN) LIMITED (KY) 2004-11-11 — — WO disclosed
US-6812233-B1 1-(2-HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL) FLUOROCYTOSINE; ADMINISTERING HEPATITIS B VIRUS TREATMENT EMORY UNIVERSITY 2004-11-02 — — US disclosed
EP-1468687-A1 Compounds for the treatment of cancer University of Georgia Research Foundation, Inc. (US) 2004-10-20 — — EP disclosed
US-6803455-B2 PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2004-10-12 — — US disclosed
US-6784166-B2 FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS SYNTEX (U.S.A.) LLC 2004-08-31 — — US disclosed
EP-1439177-A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane EMORY UNIVERSITY (US) 2004-07-21 — — EP disclosed
WO-2004056831-A1 PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION ASTRAZENECA AB (SE) 2004-07-08 — — WO disclosed
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 — — US disclosed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 — — US disclosed
EP-1404347-A2 4'-SUBSTITUDED NUCLEOSIDES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-07 — — EP disclosed
US-20030236216-A1 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC 2003-12-25 — — US disclosed
WO-2003093472-A2 CGRP BINDING NUCLEIC ACIDS Grünenthal GmbH (DE) 2003-11-13 — — WO disclosed
US-6642245-B1 Treatment of HIV and HBV infections in humans EMORY UNIVERSITY 2003-11-04 — — US disclosed
WO-2002018404-A9 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HOFFMANN LA ROCHE (CH) 2003-10-02 — — WO disclosed
EP-1177201-B1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORP (JP) 2003-09-24 — — EP disclosed
EP-1177202-B1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORP (JP) 2003-09-24 — — EP disclosed
CN-1111409-C Application of cytosine derivative in preparing medicine for treating tumor UNIV GEORGIA (US) 2003-06-18 — — CN disclosed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 — — EP disclosed
US-20030096830-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2003-05-22 — — US disclosed
US-20030032797-A1 Process for the preparation of cytidine derivatives MITSUI CHEMICALS, INC. (JP) 2003-02-13 — — US disclosed
US-20030028013-A1 Novel nucleosides having bicyclic sugar moiety CEQUENT PHARMACEUTICALS, INC. 2003-02-06 — — US disclosed
EP-1117669-B1 ANTIVIRAL PURINE DERIVATIVES UNIV CARDIFF (GB) 2003-01-29 — — EP disclosed
EP-1070074-B1 PHOSPHORUS COMPOUNDS AS CORROSION INHIBITORS FOR PERFLUOROPOLYETHERS DU PONT (US) 2003-01-15 — — EP disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 — — US disclosed
WO-2002100415-A2 4'-SUBSTITUTED NUCLEOSIDES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-19 — — WO disclosed
US-6492347-B2 TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2002-12-10 — — US disclosed
EP-0741741-B1 MODIFIED OLIGONUCLEOTIDES NOVARTIS AG (CH) 2002-08-28 — — EP disclosed
US-6436948-B1 AND OTHER HYPERPROLIFERATIVE KERATINOCYTE DISEASES SUCH AS HYPERKERATOSIS, ICHTHYOSIS, KERATODERMA OR LICHEN PLANUS; ANTICANCER, ANTITUMOR; PRODRUG FORMS OF (-)-(2S,4S)-1-(2-HYDROXYMETHYL-1,3-DIOXOLAN-4-YL)CYTOSINE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. 2002-08-20 — — US disclosed
EP-0574487-B1 USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B UNIV EMORY (US) 2002-06-19 — — EP disclosed
US-6403568-B1 FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) YAMASA CORPORATION (JP) 2002-06-11 — — US disclosed
US-6403566-B1 CONFORMATIONALLY LOCKED; ANTIVIRAL, ANTICANCER, STABILITY TO CELLULAR NUCLEASES AND STRONG BINDING AFFINITY TO NUCLEIC ACID TARGETS. ICN PHARMACEUTICALS, INC. 2002-06-11 — — US disclosed
EP-1023308-A4 INHIBITORS OF NUCLEOSIDE METABOLISM EINSTEIN COLL MED (US) 2002-05-29 — — EP disclosed
US-20020061898-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2002-05-23 — — US disclosed
EP-1186612-A1 PROCESS FOR THE PREPARATION OF CYTIDINE DERIVATIVES Mitsui Chemicals, Inc. (JP) 2002-03-13 — — EP disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 — — WO disclosed
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds OHRUI HIROSHI (JP) 2002-02-21 — — US disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 — — EP disclosed
EP-1177201-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 — — EP disclosed
EP-0761668-B1 Non-classical antifolates UNIV PRINCETON (US) 2002-01-30 — — EP disclosed
EP-0904271-A4 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES UNIV PRINCETON (US) 2002-01-23 — — EP disclosed
EP-1082012-A4 NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY ICN PHARMACEUTICALS (US) 2002-01-16 — — EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 — — US disclosed
US-20010031745-A1 Antiviral purine derivatives UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2001-10-18 — — US disclosed
EP-1142891-A1 Use of 5-Fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B EMORY UNIVERSITY (US) 2001-10-10 — — EP disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 — — US disclosed
EP-1117669-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) 2001-07-25 — — EP disclosed
US-6228847-B1 ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR ALBERT EINSTEIN COLLEGE OF MEDICINE 2001-05-08 — — US disclosed
EP-1082012-A1 NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY ICN Pharmaceuticals, Inc. (US) 2001-03-14 — — EP disclosed
US-6201116-B1 FLUORESCENT COMPOUND WITH MIMIMAL PHOTOBLEACHING, REDUCED TOXICITY, RAPID LOADING INTO CYTOPLASM, UNIFORM DISTRIBUTION, CHEMICAL STABILITY; DRUG SCREENING OF MODULATORS OF TRANSPORT PROTEINS (CYSTIC FIBROSIS); MONITORING GENE THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-03-13 — — US disclosed
US-6184187-B1 PARTIALLY AND FULLY ESTERIFIED ARYL PHOSPHORUS COMPOUNDS WHERE SOME OF THE PERFLUOROALKYL SUBSTITUTION IN PRIOR ART IS REPLACED WITH ARYL OR ARYLOXY SUBSTITUENTS; RUST RESISTANCE TO METALS IN CONTACT WITH PERFLUOROPOLYETHER LUBRICANTS E. I. DUPONT DE NEMOURS AND COMPANY 2001-02-06 — — US disclosed
EP-1070074-A1 PHOSPHORUS COMPOUNDS AS CORROSION INHIBITORS FOR PERFLUOROPOLYETHERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-01-24 — — EP disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 — — WO disclosed
WO-2000069876-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 — — WO disclosed
WO-2000058289-A1 HALIDE INDICATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-10-05 — — WO disclosed
US-6107288-A Antiviral nucleoside combination FURMAN JR PHILLIP ALLEN (US) 2000-08-22 — — US disclosed
EP-0707481-B1 L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS UNIV YALE (US) 2000-08-16 — — EP disclosed
EP-1023308-A1 INHIBITORS OF NUCLEOSIDE METABOLISM ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2000-08-02 — — EP disclosed
US-6066447-A INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS NOVARTIS CORPORATION (US) 2000-05-23 — — US disclosed
US-6066639-A ANTITUMOR AGENTS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2000-05-23 — — US disclosed
US-6066722-A Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2000-05-23 — — US disclosed
US-6063787-A SKIN DISORDERS TREATMENT WITH AMINOPYRIMIDONES SUBSTITUTED WITH HETEROCYCLIC DIETHERS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION CENTER (US) 2000-05-16 — — US disclosed
WO-2000018775-A1 ANTIVIRAL PURINE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2000-04-06 — — WO disclosed
EP-0984013-A2 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1, 3-oxathiolane EMORY UNIVERSITY (US) 2000-03-08 — — EP disclosed
US-6001818-A VIRICIDES; AIDS THERAPY YALE UNIVERSITY (US) 1999-12-14 — — US disclosed
WO-1999060855-A1 NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY ICN PHARMACEUTICALS, INC. (US) 1999-12-02 — — WO disclosed
US-5985848-A EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 1999-11-16 — — US disclosed
WO-1999051612-A1 PHOSPHORUS COMPOUNDS AS CORROSION INHIBITORS FOR PERFLUOROPOLYETHERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-10-14 — — WO disclosed
EP-0574457-B1 ANTIVIRAL NUCLEOSIDE COMBINATION WELLCOME FOUND (GB) 1999-10-13 — — EP disclosed
EP-0608809-B1 Antiviral tetrahydropyrans BRISTOL MYERS SQUIBB CO (US) 1999-07-07 — — EP disclosed
US-5914331-A Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane EMORY UNIVERSITY (US) 1999-06-22 — — US disclosed
WO-1999019338-A1 INHIBITORS OF NUCLEOSIDE METABOLISM ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 1999-04-22 — — WO disclosed
EP-0904271-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1999-03-31 — — EP disclosed
US-5830881-A L-2'3',dideoxy nucleoside analogs as anti-hepatitus B (HBV) agents YALE UNIVERSITY (US) 1998-11-03 — — US disclosed
EP-0639582-B1 Polynucleotide assay reagent and method ANTIVIRALS INC (US) 1998-09-16 — — EP disclosed
US-5786358-A INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-07-28 — — US disclosed
WO-1998000426-A1 5,6,7,8-TETRAHYDROPYRIMIDO[4,5-b]AZEPINE DERIVATIVES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-01-08 — — WO disclosed
WO-1997049705-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-12-31 — — WO disclosed
WO-1997041115-A1 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-11-06 — — WO disclosed
CN-1160351-A Compounds for treating cancer and methods of treating cancer UNIV GEORGIA (US) 1997-09-24 — — CN disclosed
EP-0481754-B1 Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines SQUIBB & SONS INC (US) 1997-08-20 — — EP disclosed
EP-0781136-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1997-07-02 — — EP disclosed
US-5631239-A VIRICIDES FOR HEPATITIS YALE UNIVERSITY (US) 1997-05-20 — — US disclosed
US-5627160-A L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents YALE UNIVERSITY (US) 1997-05-06 — — US disclosed
EP-0761668-A2 Non-classical antifolates THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-03-12 — — EP disclosed
JP-H0959292-A PRODUCTION OF 4-AMINOPYRIMIDINE NUCLEOSIDE YAMASA SHOYU CO LTD 1997-03-04 — — JP disclosed
US-5561120-A LOW TOXICITY TO HOST CELLS YALE UNIVERSITY (US) 1996-10-01 — — US disclosed
US-5539097-A NUCLEOSIDE PRIMER WHICH ALLOWS EASY RELEASE OF OLIGOMER, OXIDATATIVE CLEAVAGE, PROTECTING GROUPS MOLECULAR BIOSYSTEMS, INC. (US) 1996-07-23 — — US disclosed
EP-0707481-A4 — — 1996-05-29 — — EP disclosed
US-5521163-A TREATMENT OF HERPES VIRUS WITH 1'-DEOXY-5-ETHYL-4'-THIO-BETA URIDINE UNIVERSITY OF BIRMINGHAM (GB) 1996-05-28 — — US disclosed
EP-0707481-A1 L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS YALE UNIVERSITY (US) 1996-04-24 — — EP disclosed
EP-0576230-B1 2'-deoxy-2', 2'-difluoro(4-substituted pyrimidine) nucleosides having antiviral and anti-cancer activity and intermediates LILLY CO ELI (US) 1996-04-24 — — EP disclosed
WO-1996011204-A1 NOVEL β-L-NUCLEOSIDES AND THEIR USE Max-Delbrück-Centrum für Molekulare Medizin (DE) 1996-04-18 — — WO disclosed
WO-1996007413-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1996-03-14 — — WO disclosed
EP-0432677-B1 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives UNIV PRINCETON (US) 1996-03-06 — — EP disclosed
EP-0421777-B1 Further antiviral pyrimidine nucleosides UNIV BIRMINGHAM (GB) 1996-02-28 — — EP disclosed
EP-0458363-B1 Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines SQUIBB & SONS INC (US) 1996-02-07 — — EP disclosed
US-5430026-A Anticancer agents, viricides ELI LILLY AND COMPANY (US) 1995-07-04 — — US disclosed
EP-0658166-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES THE UNIVERSITY OF BIRMINGHAM (GB) 1995-06-21 — — EP disclosed
JP-H07145058-A PRODUCTION OF 2',3'-DIDEOXYCYTIDIN-2'-ENE (2',3'-DIDEOXY-2',3'-DIDEHYDROCYTIDINE) FOR TREATING PATIENT INFECTED WITH RETROVIRUS UNIV YALE 1995-06-06 — — JP disclosed
US-5414096-A Antiviral tetrahydropyrans BRISTOL-MYERS SQUIBB CO. (US) 1995-05-09 — — US disclosed
US-5414000-A And an imidazopyridinyl substituted tetrahydropyran BRISTOL-MYERS SQUIBB CO. (US) 1995-05-09 — — US disclosed
EP-0639582-A2 Polynucleotide assay reagent and method ANTIVIRALS INC. (US) 1995-02-22 — — EP disclosed
EP-0630897-A2 3-Hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines BRISTOL-MYERS SQUIBB COMPANY (US) 1994-12-28 — — EP disclosed
WO-1994027616-A1 L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS YALE UNIVERSITY (US) 1994-12-08 — — WO disclosed
US-5362866-A Oligonucleotide polymeric support system with an oxidation cleavable link MOLECULAR BIOSYSTEMS, INC. (US) 1994-11-08 — — US disclosed
US-5356882-A Treating herpes virus UNIVERSITY OF BIRMINGHAM (GB) 1994-10-18 — — US disclosed
US-5350749-A Fungicides, insecticides and miticides DOWELANCO (US) 1994-09-27 — — US disclosed
US-5344932-A N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives TRUSTEES OF PRINCETON UNIVERSITY (US) 1994-09-06 — — US disclosed
US-5340816-A Viricides; administering to treat herpes simplex virus, varicella zoster virus and human cytomegalovirus infections E. R. SQUIBB & SONS, INC. (US) 1994-08-23 — — US disclosed
EP-0343801-B1 N-(5,6,7,8-tetrahydropyrido(2,3-D)pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives UNIV PRINCETON (US) 1994-08-03 — — EP disclosed
EP-0608809-A1 Antiviral tetrahydropyrans BRISTOL-MYERS SQUIBB COMPANY (US) 1994-08-03 — — EP disclosed
EP-0394893-B1 Purinyl and pyrimidinyl tetrahydrofurans SQUIBB & SONS INC (US) 1994-06-29 — — EP disclosed
US-5314893-A Antiviral tetrahydropyrans BRISTOL-MYERS SQUIBB CO. (US) 1994-05-24 — — US disclosed
WO-1994005687-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1994-03-17 — — WO disclosed
JP-H0656876-A NUCLEOSIDE COMPOUND HAVING ANTIVIRAL ACTIVITY AND ANTICANCER ACTIVITY ELI LILLY & CO 1994-03-01 — — JP disclosed
EP-0583274-A1 USE OF A 1,3-OXATHIOLAN DERIVATIVE FOR THE TREATMENT OF HEPATITIS B INFECTION THE WELLCOME FOUNDATION LIMITED (GB) 1994-02-23 — — EP disclosed
EP-0316017-B1 2',3'-Dideoxy-2'-fluoronucleosides BRISTOL MYERS SQUIBB CO (US) 1994-01-19 — — EP disclosed
EP-0576230-A1 2'-deoxy-2', 2'-difluoro(4-substituted pyrimidine) nucleosides having antiviral and anti-cancer activity and intermediates ELI LILLY AND COMPANY (US) 1993-12-29 — — EP disclosed
EP-0575482-A1 ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE EMORY UNIVERSITY (US) 1993-12-29 — — EP disclosed
EP-0574487-A1 USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B THE WELLCOME FOUNDATION LIMITED (GB) 1993-12-22 — — EP disclosed
EP-0574457-A1 ANTIVIRAL NUCLEOSIDE COMBINATION THE WELLCOME FOUNDATION LIMITED (GB) 1993-12-22 — — EP disclosed
US-5248775-A Pyrrolo(2,3-d)pyrimidines THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1993-09-28 — — US disclosed
US-5234913-A Synergistic mixture of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocystosine and zidovudine BURROUGHS WELLCOME CO. (US) 1993-08-10 — — US disclosed
US-5231174-A 2'isodideoxy-β-D-nucleosides as stable antiviral agents UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1993-07-27 — — US disclosed
US-5218106-A From 2'-doexy-2'-fluoronucleosides; viricides BRISTOL-MYERS COMPANY (US) 1993-06-08 — — US disclosed
US-5206244-A Viricides E. R. SQUIBB & SONS, INC. (US) 1993-04-27 — — US disclosed
US-5204456-A Derivatives of nucleosides and their use for the synthesis of oligonucleotides COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1993-04-20 — — US disclosed
US-5179200-A N4-(3-PHENYLPROPRIONYL)-2'-DEOXYCYTIDINE COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1993-01-12 — — US disclosed
US-5164520-A Chemical intermediates for viricides E. R. SQUIBB & SONS, INC. (US) 1992-11-17 — — US disclosed
WO-1992019246-A1 USE OF A 1,3-OXATHIOLAN DERIVATIVE FOR THE TREATMENT OF HEPATITIS B INFECTION THE WELLCOME FOUNDATION LIMITED OF UNICORN HOUSE (GB) 1992-11-12 — — WO disclosed
WO-1992015309-A1 ANTIVIRAL NUCLEOSIDE COMBINATION THE WELLCOME FOUNDATION LIMITED (GB) 1992-09-17 — — WO disclosed
WO-1992015308-A1 USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B THE WELLCOME FOUNDATION LIMITED (GB) 1992-09-17 — — WO disclosed
US-5145960-A Viricides E. R. SQUIBB & SONS, INC. (US) 1992-09-08 — — US disclosed
WO-1992014743-A2 ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE EMORY UNIVERSITY (US) 1992-09-03 — — WO disclosed
EP-0261595-B1 PHARMACEUTICAL COMPOSITION COMPRISING 2',3'-DIDEOXYCYTIDIN-2'-ENE(2',3'-DIDEHYDROCYTIDINE) FOR TREATING PATIENTS INFECTED WITH RETROVIRUS YALE UNIVERSITY (US) 1992-09-02 — — EP disclosed
US-5126506-A Deoxygenation at 3-position of furan ring BRISTOL-MYERS COMPANY (US) 1992-06-30 — — US disclosed
EP-0287215-B1 THERAPEUTIC NUCLEOSIDES THE WELLCOME FOUNDATION LIMITED (GB) 1992-06-17 — — EP disclosed
EP-0486477-A2 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound THE WELLCOME FOUNDATION LIMITED (GB) 1992-05-20 — — EP disclosed
EP-0481754-A2 Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines E.R. Squibb & Sons, Inc. (US) 1992-04-22 — — EP disclosed
US-5099010-A Antitumor agents RESEARCH CORPORATION (US) 1992-03-24 — — US disclosed
EP-0361831-B1 ANTIVIRAL NUCLEOSIDE COMBINATION THE WELLCOME FOUNDATION LIMITED (GB) 1992-01-22 — — EP disclosed
WO-1991018969-A1 FLUORINATED BIS(HYDROXYMETHYL)CYCLOBUTYL PURINES AND PYRIMIDINES E.R. SQUIBB & SONS, INC. (US) 1991-12-12 — — WO disclosed
EP-0458363-A1 Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines E.R. SQUIBB & SONS, INC. (US) 1991-11-27 — — EP disclosed
US-5064946-A 3-azido-2,3-dideoxy-B-D-erythro-pentofuranosyl derivatives of 4(1H)-pyrimidinones; antiretroviral, anti-AIDS BURROUGHS WELLCOME CO. (US) 1991-11-12 — — US disclosed
EP-0453247-A2 Anti-viral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-10-23 — — EP disclosed
US-5059690-A Viricides E. R. SQUIBB & SONS, INC. (US) 1991-10-22 — — US disclosed
EP-0452002-A2 Thienopyrimidine derivatives DOWELANCO (US) 1991-10-16 — — EP disclosed
US-5041543-A AZT intermediate BURROUGHS WELLCOME CO. (US) 1991-08-20 — — US disclosed
US-5034393-A Fungicides for plants DOWELANCO (US) 1991-07-23 — — US disclosed
US-5028608-A Antineoplastic Agents THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-07-02 — — US disclosed
US-5028596-A Varicella Zoster BURROUGHS WELLCOME CO. (US) 1991-07-02 — — US disclosed
EP-0432677-A1 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-06-19 — — EP disclosed
WO-1991004982-A1 FURTHER ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1991-04-18 — — WO disclosed
EP-0421777-A1 Further antiviral pyrimidine nucleosides THE UNIVERSITY OF BIRMINGHAM (GB) 1991-04-10 — — EP disclosed
EP-0417560-A1 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-03-20 — — EP disclosed
US-4996206-A Antitumor agent THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-02-26 — — US disclosed
WO-1991001326-A1 ANTIVIRAL PYRIMIDINE NUCLEOSIDES UNIVERSITY OF BIRMINGHAM (GB) 1991-02-07 — — WO disclosed
EP-0409575-A1 Antiviral pyrimidine nucleosides THE UNIVERSITY OF BIRMINGHAM (GB) 1991-01-23 — — EP disclosed
US-4980460-A Protected nucleosides which permit more efficient oligonucleotide syntheses COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1990-12-25 — — US disclosed
US-4973677-A ANTIVIRAL AGENTS, TREATMENT OF AIDS BRISTOL-MYERS COMPANY (US) 1990-11-27 — — US disclosed
EP-0394893-A2 Purinyl and pyrimidinyl tetrahydrofurans E.R. SQUIBB & SONS, INC. (US) 1990-10-31 — — EP disclosed
EP-0391411-A2 3'-Substituted methyl nucleosides as antiviral agents Bristol-Myers Squibb Company (US) 1990-10-10 — — EP disclosed
EP-0381335-A1 Antiviral agent and novel nucleoside TANABE SEIYAKU CO., LTD. (JP) 1990-08-08 — — EP disclosed
EP-0361831-A1 Antiviral nucleoside combination THE WELLCOME FOUNDATION LIMITED (GB) 1990-04-04 — — EP disclosed
US-4908440-A 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides BRISTOL MYERS COMPANY (US) 1990-03-13 — — US disclosed
US-4883799-A N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-11-28 — — US disclosed
US-4882334-A ANTITUMOR AGENTS INHIBIT ENZYMES WHICH USE FOLIC ACID OR ITS METABOLITES AS SUBSTRATE; ANTICARCINOGENIC THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-11-21 — — US disclosed
US-4882333-A ANTICARCINOGENIC AGENTS; INHIBIT ENZYMES WHICH USE FOLIC ACID OR METABOLITES AS SUBSTRATE THE TRUSTESS OF PRINCETON UNIVERSITY (US) 1989-11-21 — — US disclosed
EP-0316017-A2 2',3'-Dideoxy-2'-fluoronucleosides Bristol-Myers Squibb Company (US) 1989-05-17 — — EP disclosed
EP-0287215-A2 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1988-10-19 — — EP disclosed
EP-0215942-A4 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1988-08-23 — — EP disclosed
EP-0272065-A2 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1988-06-22 — — EP disclosed
EP-0261595-A2 Pharmaceutical composition comprising 2',3'-Dideoxycytidin-2'-Ene(2',3'-Didehydrocytidine) for treating patients infected with retrovirus YALE UNIVERSITY (US) 1988-03-30 — — EP disclosed
EP-0259752-A2 Saccharide phosphates, their esters and method for their preparation BAYER AG (DE) 1988-03-16 — — EP disclosed
EP-0217580-A2 Therapeutic nucleosides THE WELLCOME FOUNDATION LIMITED (GB) 1987-04-08 — — EP disclosed
EP-0215942-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1987-04-01 — — EP disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 — — WO disclosed
US-4604382-A ANTITUMER AGENTS RESEARCH CORPORATION (US) 1986-08-05 — — US disclosed
EP-0155950-A4 OLIGONUCLEOTIDE POLYMERIC SUPPORT SYSTEM. MOLECULAR BIOSYSTEMS INC (US) 1986-04-15 — — EP disclosed
EP-0155950-A1 OLIGONUCLEOTIDE POLYMERIC SUPPORT SYSTEM. MOLECULAR BIOSYSTEMS INC (US) 1985-10-02 — — EP disclosed
WO-1985001051-A1 OLIGONUCLEOTIDE POLYMERIC SUPPORT SYSTEM MOLECULAR BIOSYSTEMS, INC. (US) 1985-03-14 — — WO disclosed
JP-S59190997-A PHOSPHORIC ACID ESTER DERIVATIVE DAI ICHI SEIYAKU CO LTD 1984-10-29 — — JP disclosed
US-4474947-A Benzazolides and their employment in phosphate ester oligonucleotide synthesis processes BIOSEARCH (US) 1984-10-02 — — US disclosed
JP-S58135896-A SELECTIVE PHOSPHORYLATING REAGENT IN THE 5'-POSITION OF NUCLEOSIDES MITSUI TOATSU CHEM INC 1983-08-12 — — JP disclosed
US-4393010-A Nucleosidic phosphorylating agent and methods GENENTECH, INC. (US) 1983-07-12 — — US disclosed
US-4376064-A OXYGENATED COMPOUND OF PHOSPHORUS STANDARD OIL CO. (INDIANA) (US) 1983-03-08 — — US disclosed
US-4310662-A Nucleosidic phosphorylating agent and methods GENENTECH, INC. (US) 1982-01-12 — — US disclosed
US-4144394-A FLAME RETARDANTS FOR POLYMERS MONSANTO COMPANY (US) 1979-03-13 — — US disclosed
US-4124400-A Flame retardant polymer compositions MONSANTO COMPANY (US) 1978-11-07 — — US disclosed
US-4086302-A FLAME RETARDANTS MONSANTO COMPANY (US) 1978-04-25 — — US disclosed
US-4062909-A FIRE RETARDANTS MONSANTO COMPANY (US) 1977-12-13 — — US disclosed
US-4000239-A PROCESS FOR SPINNING NAPHTHALATE POLYESTER FIBERS TEIJIN LIMITED (JA) 1976-12-28 — — US disclosed
US-4000239-A PROCESS FOR SPINNING NAPHTHALATE POLYESTER FIBERS TEIJIN LIMITED (JA) 1976-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078970-A1 PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER ABL1, FLT3, SRC MEN1 1705/4885KMT2A 1351/4885HPGD 1093/4885
US-20140369959-A1 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RNGTT, NSUN2, NSUN3 MEN1 4587/4885KMT2A 1147/4885HPGD 4174/4885
US-20030028013-A1 Novel nucleosides having bicyclic sugar moiety DCK, NUDT14, UCK2 MEN1 3823/4885KMT2A 2320/4885HPGD 3738/4885
US-20180105551-A1 TRINUCLEOTIDE MRNA CAP ANALOGS RNGTT, RNMT, NSUN2 MEN1 1689/4885KMT2A 2288/4885HPGD 3015/4885
US-20050004148-A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane PNP, MTAP, ENTPD5 MEN1 3749/4885KMT2A 3742/4885HPGD 1873/4885
US-20030032797-A1 Process for the preparation of cytidine derivatives CDA, DCTD, APOBEC3A MEN1 3308/4885KMT2A 1626/4885HPGD 1464/4885
US-20250368598-A1 CATALYTIC CARBOXYCARBONYLATION OF ALKENES TO FORM ANHYDRIDES CA4, CA12, CA14 MEN1 530/4885KMT2A 229/4885HPGD 2522/4885
US-20140179910-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-20130165644-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 MEN1 4680/4885KMT2A 3710/4885HPGD 2760/4885
US-20140275508-A1 ARTIFICIAL NUCLEIC ACIDS NSUN2, POLRMT, NSUN3 MEN1 897/4885KMT2A 1109/4885HPGD 1213/4885
US-20050038240-A1 Processes for preparing 4'-azido-nucleoside derivatives NUDT1, RNGTT, DUT MEN1 2811/4885KMT2A 1196/4885HPGD 1917/4885
US-20070042988-A1 Antiviral phosphoramidates RPP30, RNASE1, ADORA2B MEN1 3374/4885KMT2A 2828/4885HPGD 4398/4885
US-20140179627-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-10307439-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NT5C3B, TYMP MEN1 4072/4885KMT2A 3542/4885HPGD 488/4885
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C DPYD, TYMP, PNPO MEN1 4755/4885KMT2A 4257/4885HPGD 119/4885
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 MEN1 4883/4885KMT2A 4247/4885HPGD 2353/4885
US-20190054108-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B MEN1 3432/4885KMT2A 3185/4885HPGD 1360/4885
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds PNP, TYMP, NUDT1 MEN1 4559/4885KMT2A 4341/4885HPGD 1575/4885
US-20040266722-A1 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication NSUN2, RNGTT, NSUN3 MEN1 4434/4885KMT2A 2532/4885HPGD 4006/4885
US-20070254312-A1 Protein Kinase Inhibitors and Methods for Identiying Same PRKCA, PRKCE, PRKCB MEN1 4563/4885KMT2A 2642/4885HPGD 3000/4885
US-20250163093-A1 EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF NAPRT, NAMPT, CD38 MEN1 1545/4885KMT2A 1994/4885HPGD 915/4885
US-11345720-B2 Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof NAPRT, NAMPT, CD38 MEN1 1549/4885KMT2A 2009/4885HPGD 913/4885
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 MEN1 2330/4885KMT2A 2369/4885HPGD 3822/4885
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-20130310551-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 MEN1 4675/4885KMT2A 3726/4885HPGD 2900/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 MEN1 4883/4885KMT2A 4247/4885HPGD 2353/4885
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation HAVCR2, PNP, PCNA MEN1 4691/4885KMT2A 4077/4885HPGD 1125/4885
US-20050026936-A1 Inhibitors of nucleoside metabolism CFH, CBR3, SLCO2B1 MEN1 3266/4885KMT2A 2565/4885HPGD 849/4885
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 MEN1 2284/4885KMT2A 3824/4885HPGD 3242/4885
US-20170037077-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-20210230209-A1 AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF PRKAG1, PRKAG2, PRKAG3 MEN1 3634/4885KMT2A 3888/4885HPGD 1058/4885
US-20160039858-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-20060276492-A1 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane PNP, MTAP, ENTPD5 MEN1 3749/4885KMT2A 3742/4885HPGD 1873/4885
US-20080312227-A1 Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders PNPO, TPMT, TNF MEN1 4660/4885KMT2A 4205/4885HPGD 155/4885
US-11267844-B2 Spirothietane nucleosides SAMHD1, SLC28A1, SLC28A2 MEN1 2279/4885KMT2A 3853/4885HPGD 652/4885
US-20220112172-A1 PROCESS FOR PRODUCING DIOL CA4, CA2, CA1 MEN1 461/4885KMT2A 1882/4885HPGD 433/4885
US-20020061898-A1 Inhibitors of nucleoside metabolism PNP, APRT, NUDT14 MEN1 3541/4885KMT2A 2009/4885HPGD 849/4885
US-20050004357-A1 Industrially scalable nucleoside synthesis ADA, DCTD, PNP MEN1 2792/4885KMT2A 3613/4885HPGD 1564/4885
US-20110092460-A1 CYCLOPROPYL POLYMERASE INHIBITORS POLR2E, POLR2H, CTR9 MEN1 4310/4885KMT2A 4156/4885HPGD 3004/4885
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation HAVCR2, PNP, DCTD MEN1 4711/4885KMT2A 4065/4885HPGD 896/4885
US-20090048190-A1 Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane PNP, MTAP, ENTPD5 MEN1 3711/4885KMT2A 3460/4885HPGD 2308/4885
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP MEN1 3783/4885KMT2A 4610/4885HPGD 69/4885
US-20130137654-A1 NUCLEOSIDE PHOSPHORAMIDATES PNP, RNGTT, NSUN2 MEN1 4680/4885KMT2A 3710/4885HPGD 2760/4885
US-20150366888-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NT5C3B, TYMP MEN1 4072/4885KMT2A 3542/4885HPGD 488/4885
US-20100003213-A1 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION NSUN2, RNGTT, RNMT MEN1 4819/4885KMT2A 1509/4885HPGD 3168/4885
US-10683320-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C2 MEN1 4103/4885KMT2A 3429/4885HPGD 619/4885
US-20180079774-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B MEN1 4230/4885KMT2A 2921/4885HPGD 936/4885
US-20120309705-A1 NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES ENTPD5, MTAP, SLC29A1 MEN1 2266/4885KMT2A 2561/4885HPGD 1490/4885
US-20150038494-A1 Thiazolopyrimidine Modulators as Immunosuppressive Agents TPMT, STAT6, IL4 MEN1 2449/4885KMT2A 3592/4885HPGD 3012/4885
US-20200040026-A1 TRINUCLEOTIDE MRNA CAP ANALOGS RNGTT, RNMT, NSUN2 MEN1 1689/4885KMT2A 2288/4885HPGD 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.